Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Rebecca Anne Snyder

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2485-2481; OpenAlex author ID A5015699036. Sources: ClinicalTrials.gov.

Their work

Papers
31 (first author 3, last author 12)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
2
Collaborators
113
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 3 papers · 2023: 4 papers · 2024: 4 papers · 2025: 6 papers · 2026: 10 papers, 1 trial, 1 grant · 2027: 1 trial

Papers 31

  1. Surgical Palliation for Pancreatic Cancer. First author DOI 10.1016/j.soc.2025.05.005↗
  2. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  3. Presentation, Management, and Outcomes of Cyst-Associated Pancreatic Cancer Versus Classic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002608↗
  4. A Word of Caution: Operation Alone Remains Inadequate for Pancreatic Cancer. Last author DOI 10.1097/xcs.0000000000001735↗
  5. Contemporary Multidisciplinary Treatment of Borderline-Resectable and Locally Advanced Pancreatic Adenocarcinoma. First author DOI 10.1200/edbk-26-515560↗
  6. Racial and Ethnic Disparities in Receipt of Guideline-Concordant Pancreatic Cancer Care Among Older Adults in the United States. Last author DOI 10.1200/op-25-00351↗
  7. Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Do… Last author DOI 10.1200/op-25-01431↗
  8. Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma. Last author DOI 10.1200/po-25-00703↗
  9. Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Last author DOI 10.1245/s10434-025-18691-x↗
  10. ASO Visual Abstract: Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Last author DOI 10.1245/s10434-025-18865-7↗
  11. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1001/jamasurg.2024.5191↗
  12. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  13. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
  14. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006269↗
  15. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  16. The Landmark Series: The Future of Pancreatic Cancer Clinical Trials. Last author DOI 10.1245/s10434-024-16840-2↗
  17. Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi-institutional ana… Co-author DOI 10.1002/jso.27798↗
  18. Effect of surgical approach on early return to intended oncologic therapy after resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00464-024-11022-3↗
  19. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0↗
  20. Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A02150… Co-author DOI 10.1245/s10434-024-15670-6↗
  21. Racial disparities in pancreatic cancer clinical trials: Defining the problem and identifying solutions. First author DOI 10.1016/bs.acr.2023.02.009↗
  22. Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501). Co-author DOI 10.1097/sla.0000000000005958↗
  23. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancr… Co-author DOI 10.1245/s10434-022-12741-4↗
  24. Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma. Last author DOI 10.3390/cancers15164174↗
  25. Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer. Last author DOI 10.1002/jso.26859↗
  26. Differential effects of the Affordable Care Act on the stage at presentation and receipt of treatment for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26984↗
  27. Opportunity Costs of Surgical Resection and Perioperative Chemotherapy for Locoregional Pancreatic Adenocarcinoma. Last author DOI 10.1200/op.21.00311↗
  28. Thirty-day complication rates do not differ by race among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. Last author DOI 10.1002/jso.26383↗
  29. Actual Survival in Patients with Resected Pancreatic Cancer: How Do Real-World Data Compare with Clinical Trial Evidence? Co-author DOI 10.1245/s10434-021-10532-x↗
  30. Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimi… Co-author DOI 10.1016/j.hpb.2018.10.018↗
  31. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.30117↗

Trials 2

  1. Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient … Principal investigator NCT07829471↗
  2. Barriers And Facilitators To Clinical Trial Enrollment: A Qualitative Study Of Pancreatic Cancer Patients Principal investigator NCT07591480↗

Grants 1

  1. FY2026 Lustgarten grant: Rebecca Snyder; Heather Lyu AWARD lustgarten:2026-rebecca-snyder-heather-lyu-fy2026-lustgarten-grant-rebecca-snyder-h

Closest collaborators

The 25 strongest of 113 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 20 shared papers, 2016–2026 · strength 4.75
  2. Ching-Wei David Tzeng · 9 shared papers, 2019–2026 · strength 1.97
  3. Naruhiko Ikoma · 8 shared papers, 2024–2026 · strength 1.87
  4. Michael P. Kim · 8 shared papers, 2019–2026 · strength 1.77
  5. Laura R. Prakash · 8 shared papers, 2016–2026 · strength 1.66
  6. Alexander A. Parikh · 8 shared papers, 2021–2025 · strength 1.51
  7. Jeffrey E. Lee · 7 shared papers, 2016–2026 · strength 1.44
  8. Robert A. Wolff · 6 shared papers, 2016–2026 · strength 0.97
  9. Eugene Jon Koay · 6 shared papers, 2016–2026 · strength 0.97
  10. Mahmoud Yousef · 5 shared papers, 2024–2026 · strength 0.96
  11. Brandon George Smaglo · 5 shared papers, 2024–2026 · strength 0.93
  12. Shubham Pant · 5 shared papers, 2024–2026 · strength 0.93
  13. Anirban Maitra · 6 shared papers, 2016–2026 · strength 0.91
  14. Adriana Carolina Gamboa · 2 shared papers, 2026 · strength 0.88
  15. Eileen Mary O'Reilly · 4 shared papers, 2023–2026 · strength 0.86
  16. Pamela W. Lu · 3 shared papers, 2024–2026 · strength 0.77
  17. Dan Zhao · 4 shared papers, 2024–2026 · strength 0.77
  18. Michael James Overman · 5 shared papers, 2016–2026 · strength 0.76
  19. Anastasios T. Mitsakos · 4 shared papers, 2021–2022 · strength 0.73
  20. Joseph M. Herman · 3 shared papers, 2023–2026 · strength 0.71
  21. Abdelrahman M.G. Yousef · 4 shared papers, 2024–2026 · strength 0.71
  22. Rachel Hae‐Soo Joung · 1 shared paper, 2026 · strength 0.63
  23. Ryan W. Huey · 3 shared papers, 2025–2026 · strength 0.58
  24. Syed Ameen Ahmad · 3 shared papers, 2023–2025 · strength 0.57
  25. Robin D. Wright · 2 shared papers, 2026 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.